500
Participants
Start Date
November 23, 2020
Primary Completion Date
April 2, 2021
Study Completion Date
February 1, 2022
Group A (AG0302-COVID19)
2 mg of AG0302-COVID19 twice at 2-week intervals
Group A (Placebo)
Placebo twice at 2-week intervals
Group B (AG0302-COVID19)
2 mg of AG0302-COVID19 twice at 4-week intervals
Group B (Placebo)
Placebo twice at 4-week intervals
UHW Narita Hospital, Narita
Medical Corporation Heishinkai OCROM Clinic, Suita
Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic, Shibuya-ku
Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku
Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku
Sekino Clinical Pharmacology Clinic, Toshima-ku
NISHI-UMEDA Clinic for Asian Medical Collaboration, Osaka
Medical Corporation Heishinkai OPHAC Hospital, Osaka
Collaborators (1)
Japan Agency for Medical Research and Development
OTHER_GOV
AnGes, Inc.
INDUSTRY